Tag: Bevacizumab

Clinical Data Clinical Trials Healthcare & Pharmaceuticals News Oncology

Eli Lilly Sofe-M Plus Bevacizumab Delivers 79% Response Rate in Platinum-Sensitive Ovarian Cancer at ESMO 2026

Eli Lilly and Company News

Lilly Sofe-M, an investigational FRα-targeting antibody-drug conjugate, combined with bevacizumab produced a 79.3% confirmed objective response rate and 100% disease control in platinum-sensitive ovarian cancer in Phase 1 data, to be presented orally at ESMO 2026 in Madrid.

Clinical Trials Cancer Healthcare & Pharmaceuticals News

Pfizer’s BRAFTOVI® Combination Regimen Halves Mortality Risk in BRAF V600E-Mutant Metastatic Colorectal Cancer

pfizer news

Pfizer’s BRAFTOVI® combination regimen has demonstrated a 51% reduction in the risk of death and a 47% decrease in disease progression for patients with BRAF V600E-mutant metastatic colorectal cancer, according to the pivotal Phase 3 BREAKWATER trial.